S100A9 and myelodysplastic syndrome: Most importantly, they showed in vivo that the treatment of S100A9 Tg mice with the anti-PD1 inhibitor significantly improves the colony-forming capacity of the BM cells and increases most of the hematological parameters, further reinforcing the role of this pathway in the ineffective hematopoiesis of MDS.